The Center for Biosimilars® recaps the top 5 articles for the week of May 28, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 28.
Number 5: Drug maker Lupin has announced that its marketing authorization application for a proposed etanercept biosimilar was accepted for review by the European Medicines Agency.
Number 4: A new study concludes that most patients can self-administer Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo, using an auto-injector device.
Number 3: After having received a Complete Response Letter, biosimilar developer Celltrion has resubmitted its application for a proposed rituximab biosimilar, CT-P10, to the FDA.
Number 2: New research describes how much the European Union is overspending on neovascular age-related macular degeneration treatment by relying on ranibizumab and aflibercept rather than bevacizumab.
Number 1: FDA Commissioner Scott Gottlieb, MD, has announced new draft guidance documents aimed at limiting the potential for drug makers to abuse Risk Evaluation and Mitigation Strategy requirements.
Finally, last week, our e-newsletter asked whether you think that a recent study showing that 6 months of trastuzumab therapy is as good as 1 year will change clinical practice.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.